Session » (0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II
- 10:30AM-12:30PM
-
Abstract Number: 0915
A fusion of TACI variant and anti-IFNAR antibody with greater therapeutic effect on related autoimmune disease models
- 10:30AM-12:30PM
-
Abstract Number: 0902
A Novel Approach to study ANA+ B Cells in Lupus Integrating Flow Cytometry with Single-Cell culture
- 10:30AM-12:30PM
-
Abstract Number: 0911
A Novel FcRn × Albumin Bispecific Antibody Demonstrates Extended Half-life and Deep IgG Reduction in Preclinical Mouse Models
- 10:30AM-12:30PM
-
Abstract Number: 0899
Altered B cell Subsets Shared in Immune Checkpoint Inhibitor Associated Sicca Syndrome and Sjogren’s Disease
- 10:30AM-12:30PM
-
Abstract Number: 0897
APECED Disease Reorganizes The B Cell Compartment Toward Alternatively Activated Subsets
- 10:30AM-12:30PM
-
Abstract Number: 0912
CD11c⁺CD21⁻ Autoimmune-Associated B Cells Derived from Double-Negative IgD⁻CD27⁻ Subsets Exhibit Enhanced IFNLR1 Expression in Systemic Lupus Erythematosus
- 10:30AM-12:30PM
-
Abstract Number: 0907
Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling
- 10:30AM-12:30PM
-
Abstract Number: 0901
Data-Driven Metabolomics Identifies Diagnostic Signatures and Patient Subgroups in Systemic Autoimmune Disorders
- 10:30AM-12:30PM
-
Abstract Number: 0905
Development and Characterization of IAR130, a 2+1 Format, CD19 and BCMA Dual Targeting T Cell Engager for Autoimmune Diseases
- 10:30AM-12:30PM
-
Abstract Number: 0910
Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
- 10:30AM-12:30PM
-
Abstract Number: 0898
Distinct B Cell and Plasma Cell Immunosuppression Strategies Eliminate Antigen-Specific Cells of the B Lineage
- 10:30AM-12:30PM
-
Abstract Number: 0908
E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease
- 10:30AM-12:30PM
-
Abstract Number: 0903
Ianalumab‘s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell-activating factor receptor signaling
- 10:30AM-12:30PM
-
Abstract Number: 0909
Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
- 10:30AM-12:30PM
-
Abstract Number: 0913
Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
- 10:30AM-12:30PM
-
Abstract Number: 0906
Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
- 10:30AM-12:30PM
-
Abstract Number: 0914
Preclinical Expansion of Autoreactive Naive B cells Drives RA onset in ACPA+ individuals
- 10:30AM-12:30PM
-
Abstract Number: 0900
Profiling of Novel Autoantibodies for Prediction of Disease Activity in ANCA-Associated Vasculitis
- 10:30AM-12:30PM
-
Abstract Number: 0904
SLAMF7 Drives Plasma Cell Differentiation in Rheumatoid Arthritis Synovium.